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Abstract
Background: In rheumatoid arthritis (RA), synovial fibroblasts (SF) secrete large amounts of IL-6, IL-8 and matrix
metalloproteinases (MMPs) which are crucial for cartilage destruction. RASFs are sensitive to the action of
cannabinoids and they not only express cannabinoid receptors type I and II (CB1 and CB2) but also transient
receptor potential channels type vanilloid (TRPV1) and ankyrin (TRPA1). The synthetic cannabinoid WIN55,212-2
mesylate (WIN) demonstrated strong anti-inflammatory effects in monocytes and synovial fibroblasts only in high
concentrations in a non-cannabinoid receptor dependent manner. In this study we assessed the ability of WIN to
modulate cytokine and MMP-3 production in SFs over a wide concentration range and identified specific receptor
targets that mediate the effects of this synthetic cannabinoid.
Methods: MMP-3, IL-6 and IL-8 were determined by ELISA. Adhesion was measured by the XCELLigence system.
Proliferation was assessed by cell titer blue assays.
Results: WIN significantly reduced TNF-induced IL-6, IL-8 and MMP-3 production in concentrations below 2 μM,
while higher concentrations completely inhibited production of IL-6 and IL-8 but increased extracellular MMP-3
levels. The inhibitory effect at low concentrations (<2 μM) was independent on activation of either CB1 or CB2 but
was attenuated by TRPV1 or TRPA1 inhibition in OASFs and RASFs. The effects of high concentrations of WIN on
cytokine and MMP-3 production were decreased by the calcium chelating agent BAPTA, the AMPK activator
metformin, the TRPA1 antagonist A967079 and the CB2 antagonist COR170. Furthermore, fetal calf serum content
in culture media strongly influenced the efficacy of WIN at high concentrations. In addition, high concentrations
of WIN also diminished SF adhesion and proliferation without altering cell viability whereas low concentrations
promoted SF adhesion without any influence on proliferation.
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Conclusion: The synthetic cannabinoid WIN in low concentrations exhibits anti-inflammatory effects in synovial
fibroblasts independent of CB1 and CB2 while CB2 and yet unidentified receptor targets are responsible for WIN
effects in micromolar concentrations. Our results indicate a TRPV1/TRPA1 dependent mechanism of SF regulation
that might be coupled to cellular energy status and calcium content.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
autoimmune disease characterized by joint inflammation
and cartilage destruction [1]. The latter is mediated
mostly by macrophages and synovial fibroblasts (SFs)
which secrete matrix degrading enzymes, activate lym-
phocytes and invade cartilage [2, 3]. Although several
therapeutic options are available for the treatment of
RA, none of these specifically target SFs although they
are a major contributor to the disease.
Besides its role in controlling neurotransmitter release,
the endocannabinoid system influences several aspects
of the immune response where it acts mostly immune-
modulatory. Peripheral anti-inflammatory effects of
(endo-) cannabinoids have been attributed to the activa-
tion of the cannabinoid receptor 2 (CB2) while CB1 is
the major cannabinoid receptor in the central nervous
system where it controls neurotransmitter release [4, 5].
The endocannabinoid arachidonylethanolamine (ananda-
mide ;AEA) decreases proliferation and cytokine produc-
tion of T-cells and this was dependent on activation of
CB2 [6]. In collagen-induced arthritis in mice, elevation
of the endocannabinoid tone by inhibition of degrad-
ation was protective via a CB2-dependent mechanism
[7]. A similar protective effect was achieved using a syn-
thetic CB2 agonist [5]. In vitro studies with isolated syn-
ovial fibroblasts also demonstrated anti-inflammatory
effects of some synthetic cannabinoids albeit only in mi-
cromolar concentrations, possibly, not via classical can-
nabinoid receptors [8].
In this study, we investigated the mechanism of action
of one of the most widely used CB1/CB2 agonists,
WIN55,212-2 mesylate (WIN). It is demonstrated that not
cannabinoid receptors but transient receptor potential
channels (TRPs) vanilloid type 1 (TRPV1) and ankyrin
(TRPA1) mediate the anti-inflammatory effects of WIN in
physiological concentrations on rheumatoid arthritis syn-
ovial fibroblasts (RASFs) and osteoarthritis synovial fibro-
blasts (OASFs). In addition, we show that micromolar
concentrations of WIN decrease cytokine production by
activating CB2 and non-cannabinoid receptor targets. Fur-




In this study, 28 patients with long-standing RA fulfilling
the American College of Rheumatology revised criteria
for RA [9] and 56 patients with OA were included. The
RA group comprised of 21 females and 7 males with a
mean age of 61.1 years ±10.7 years; C-reactive protein
was 7.0 mg/dl ± 8.59 mg/dl. In the RA group, 23 patients
received non-steroidal anti-inflammatory drugs, 22
glucocorticoids, 11 methotrexate, 3 sulfasalazine and 2
biologicals. The OA group comprised of 31 females and 25
males with a mean age of 68.5 years ±9.2 years; C-reactive
protein was 4.7 mg/dl ± 10.4 mg/dl. In the OA group, 45
patients received non-steroidal anti-inflammatory drugs.
All patients underwent elective knee joint replacement sur-
gery, and they were informed about the purpose of the
study and gave written consent. The study was approved
by the Ethics Committee of the University of Regensburg.
Synovial fibroblast and tissue preparation
Synovial tissue samples from OA and RA were obtained
immediately after opening the knee joint capsule, the
preparation of which was recently described [10]. Pieces
of synovial tissue of up to 9 cm2 were excised. One part
of the tissue was cut, placed in protective freezing
medium and stored at −80 °C until further use (Tissue
Tek, Sakura Finetek, Zoeterwoude, The Netherlands).
Another part was minced and treated with dispase I
(Roche Diagnostics, Mannheim, Germany). Digestion
was carried out for at least 1 h at 37 °C on a shaking
platform. The resulting suspension was filtered (70 μm)
and centrifuged at 300 g for 10 min. The pellet was then
treated with erythrocyte lysis buffer (20.7 g NH4Cl,
1.97 g NH4HCO3, 0.09 g EDTA ad 1 l H2O) for 5 min
and again centrifuged for 10 min at 300 g. The pellet
was resuspended in RPMI-1640 (Sigma Aldrich, St.
Louis, USA) with 10 % FCS. Cell number was calculated
using a Neubauer cell counting chamber. A total of
100,000 cells were transferred to a 75 cm2 tissue culture
flask. After overnight incubation, cells were supple-
mented with fresh medium.
Stimulation of RA and OA synovial fibroblasts
To study cytokine and MMP-3 production, cells were
stimulated in 2 % serum-containing RPMI-1640 medium
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with respective compounds 5 h prior to addition of TNF
(10 ng/ml final concentration). Cell culture supernatants
were used for ELISAs 24 h or 48 h after addition of
compounds, respectively.
TNF, IL-6 and IL-8 ELISA
Tests were conducted as described by the supplier (BD,
OptEIA, Heidelberg, Germany). Tissue culture superna-
tants from SFs were diluted 1:13 (RASFs and OASFs)
(for IL-6 and IL-8). Inter- and intraassay coefficient of
variation was below 10 %.
Matrix metalloproteinase-3 (MMP-3) ELISA
A total of 100 μl of tissue culture supernatants were
transferred into a 96 well plate (NUNC, Langenselbold,
Germany) and frozen at −20 degrees. Plates with super-
natants were defrosted for 3 h at 37 degrees. Superna-
tants were removed and 1 % BSA in PBS was added for
1 h at room temperature to block unspecific binding.
Then, anti-MMP3 (ab52915, abcam, Cambridge, UK)
antibody was added for 1 h at room temperature
(1:1000, diluted in PBS with 1 % BSA). After washing,
secondary antibody (1:2000, goat anti-rabbit Poly-HRP,
Fisher Scientific, Schwerte, Germany) was added for 1 h
at room temperature. Authentic MMP-3 protein was ob-
tained from R&D systems.
Monitoring adhesion with the xCELLigence system
The xCELLigence system (Roche Applied Sciences,
Mannheim, Germany) enables real time monitoring of
cellular events by using impedance measurements across
interdigitated micro-electrodes integrated on the bottom
of tissue culture microtiter plates (E-plates, electrode
plates). Impedance changes occur if cells attach to E-
plates or change their size, shape and number due to
specific treatments.
For adhesion experiments, E-plates (Roche) were
coated for 1 h at room temperature with 100 μl 10 μg/
ml fibronectin (BD, Heidelberg, Germany) in PBS. To
block unspecific binding, 1 % bovine serum albumin in
PBS was added for 30 min. A total of 2000–5000 pre-
treated cells (see above) were added to the E-plates and
xCELLigence was programmed to monitor adhesion
every minute for 240 min. After 60 min of incubation,
adhesion remained linear so that time point was chosen
as the endpoint of adhesion measurement. Adhesion
was quantified by averaging data from 1 min to 60 min
of incubation. Untreated cells served as control and this
value was set to 100 %.
Statistical analysis
Statistical analysis was performed with SigmaPlot 12
(Systat Software Inc., San Jose, USA) and SPSS 20 (IBM,
Armonk, USA). The statistic tests used are given in the
figure legends. The significance level was p < 0.05.
Results
WIN reduces IL-6, IL-8 and MMP-3 production in RA and
OA synovial fibroblasts
In OASFs and RASFs, WIN (from 10−12M to 10−6M)
concentration-dependently reduced TNF-induced IL-6
(Fig. 1a), IL-8 (Fig. 1g) and MMP-3 (Fig. 1m) production
with highest efficacy in low to medium nanomolar con-
centrations. This inhibitory effect was not modulated by
either CB1 or CB2 antagonists (Fig. 1b, c, h, i, n, o) but
was attenuated by TRPV1 and TRPA1 antagonism. In
RASFs treated with WIN, the decrease in TNF-induced
IL-6 and IL-8 production was blocked by the TRPV1 an-
tagonist capsazepine (Fig. 1d, j) and by the TRPA1 an-
tagonist A967079 (Fig. 1e, k). In OASFs, only IL-8
production was modulated by TRPV1 antagonism
(Fig. 1j). Extracellular MMP-3 levels were further re-
duced by TRPV1 antagonism in WIN/TNF treated
RASFs (Fig. 1p), while TRPA1 antagonism reversed the
inhibitory effect of WIN on MMP-3 production in
OASFs (Fig. 1q). The AMPK activator metformin only
showed a trend towards modulation of WIN effects on
MMP-3 in OASFs (p = 0.058). Average control values
were 4.11 ng/ml ± 3.05 ng/ml (OASFs) and 3.82 ng/ml ±
2.68 ng/ml (RASFs) for IL-6, 4.14 ng/ml ± 4.00 ng/ml
(OASFs) and 3.60 ng/ml ± 1.58 ng/ml (RASFs) for IL-8
and 47 ng/ml ± 16 ng/ml (OASFs) and 42 ng/ml ±
17 ng/ml (RASFs) for MMP-3.
Micromolar concentrations of WIN completely inhibit
cytokine production but increase extracellular MMP-3
levels
WIN concentrations above 2 μM almost completely
abolished IL-6 and IL-8 production in OASFs and
RASFs (Fig. 2a, b), while extracellular MMP-3 levels
were either unaltered (OASFs, Fig. 2c) or increased
(RASFs, Fig. 2c). In OASFs, this strong inhibitory effect
of WIN on IL-6 and IL-8 production was not altered by
TRPV1/TRPA1 antagonism, AMPK activation by met-
formin or by removal of intracellular calcium by the che-
lating agent BAPTA-Am (Fig. 2a, b, OASFs). In RASFs,
however, the inhibitory effect of WIN on TNF-induced
IL-6 production was attenuated by i)TRPV1 and TRPA1
antagonism, ii) removal of intracellular calcium by
BAPTA-Am and iii) the AMPK activator metformin
(Fig. 2a, RASFs). IL-8 production was attenuated by
BAPTA-Am only in RASFs (Fig. 2b, RASFs). Extracellu-
lar MMP-3 was reduced by addition of the TRPV1 an-
tagonist capsazepine in OASFs and RASFs, while all
other compounds (except A967079 in RASFs) increased
extracellular MMP-3 levels (Fig. 2c). CB1 antagonism
(1 μM CP945598, data not shown) did not significantly
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modulate the effects of high WIN concentrations, while
the CB2 antagonist COR170 (10 μM) partially blocked
the effects of WIN on IL-6 in OASFs but enhanced the
effects of WIN on IL-6 production in RASFs. WIN-
induced inhibition of IL-8 production was attenuated by
COR170 in OASFs and RASFs (Fig. 3a, b). The CB2 an-
tagonist/inverse agonist COR170 (10 μM) alone reduced
IL-6 production only in RASFs (Fig. 3c) and it demon-
strated different efficacy in RASFs and OASFs to modu-
late IL-6 and IL-8 production (Fig. 3c, d).
Fig. 2 Influence of high concentrations of WIN55212-2 mesylate (WIN, 10−6M to 10−5M) with and without antagonists on TNF-induced
IL-6 (a), IL-8 (b) and MMP-3 (c) production in RA and OA synovial fibroblasts. Cytokine/MMP-3 production was determined under hypoxic (1 % O2)
conditions. ***p < 0.001 for comparisons vs control (TNF only, 100 %, dotted line). ###p < 0.001, ##p < 0.01, #p < 0.05 for comparisons vs WIN/TNF only
w/o antagonists. The general linear model with Bonferroni correction was used for all comparisons. All data are given as mean ± sem.
Calcium chelator = BAPTA-Am, TRPV1 antagonist = capsazepine, TRPA1 antagonist = A967079, AMPK activator = metformin
Fig. 1 Influence of WIN55212-2 mesylate (WIN, 10−12M to 10−6M) with and without antagonists on TNF-induced IL-6 (a-f), IL-8 (g-l) and MMP-3
(m-r) production in RA and OA synovial fibroblasts. Cytokine/MMP-3 production was determined under hypoxic (1 % O2) conditions. ***p < 0.001
for comparisons vs control (TNF only, 100 %, dotted line). ###p < 0.001, ##p < 0.01 for comparisons vs WIN/TNF only w/o antagonists. The general
linear model with Bonferroni correction was used for all comparisons. All data are given as mean ± sem. CB1 antagonist = CP945598, 1 μM; CB2
antagonist = JTE-907, 1 μM; TRPV1 antagonist = capsazepine, 1 μM; TRPA1 antagonist = A967079, 1 μM; AMPK activator =metformin, 10 μM
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Inhibitory effect of high WIN concentrations is partly
dependent on media FCS content
During above mentioned experiments, cells were cul-
tured in medium containing 2 % fetal calf serum, which
provides enough energy and growth factor input for cell
maintenance but not to commence cellular proliferation
(own observations). Therefore, the efficacy of high con-
centrations of WIN with varying amounts of FCS in cul-
ture medium was investigated. In OASFs and RASFs,
the efficacy of WIN in modulating IL-6 and IL-8 pro-
duction was highly dependent on FCS content. While
the inhibitory effect of WIN was most pronounced with-
out FCS, increasing FCS to 10 % significantly reduced its
inhibitory capacity on TNF-induced IL-6 and IL-8 pro-
duction (Fig. 4a, b). However, in concentrations above
6 μM, WIN abrogated cytokine production almost com-
pletely regardless of medium FCS content in OASFs and
RASFs. Extracellular MMP-3 was only modulated by
FCS in OASFs, with high FCS content increasing its
levels (Fig. 4c, OASFs).
WIN influences adhesion to fibronectin and proliferation
of OASFs and RASFs
Cannabinoids not only influence the production of in-
flammatory mediators but also modulate cell functional
parameters such as adhesion and proliferation. We have
Fig. 3 Influence of high concentrations of WIN55212-2 mesylate (WIN, 10−6M to 10−5M) and CB2 antagonist COR170 on TNF-induced IL-6
and IL-8 production in RA and OA synovial fibroblasts. a, b Modulation of WIN effects by CB2 antagonism on TNF-induced IL-6 and IL-8
production. c, d Impact of CB2 antagonist COR170 alone on IL-6 and IL-8 production in RASFs and OASFs. Cytokine production was determined under
hypoxic (1 % O2) conditions. *p < 0.05 for comparisons vs control (TNF only, 100 %, dotted line). For comparisons versus control (100 %)
the paired t-test was used; for comparisons between OA and RA (c, d), the t-test was used. The general linear model with Bonferroni
correction was used for comparisons between WIN only and WIN together with CB2 antagonist (a, b). Data are depicted as mean ± sem.
Corresponding p-values for comparisons are given in the graph. Data in C) and D) are visualized as box plots/vertical dot blots. The
boundary of the box closest to zero indicates the 25th percentile, the line within each box indicates the median and the upper boundary
of the box the 75th percentile. Error bars below and above the box indicate the 10th and 90th percentiles
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previously shown a stimulatory effect of CB1 and CB2
agonism on SF adhesion to fibronectin [11]. Therefore
the ability of WIN to modulate SF adhesion was investi-
gated. In OASFs and RASFs, WIN significantly modu-
lated adhesion to fibronectin in a bell-shaped manner
(Fig. 5a). While concentrations up to 100nM stimulated
adhesion, higher concentrations decreased adhesion to
fibronectin (Fig. 5a). Similar results were obtained when
proliferation was investigated with WIN up to 1 μM be-
ing without significant influence (Fig. 5b). WIN concen-
trations above 1 μM, however, completely halted cell
proliferation in OASFs and RASFs (Fig. 5b). Lactate de-
hydrogenase levels in the supernatant, a marker for cell
death, remained unaltered for at least 48 h (data not
shown).
Treatment with high WIN concentrations changes cell
morphology of SFs
Since high concentrations of WIN seem to impair OASF
and RASF function, cell morphologic changes upon
WIN treatment were investigated (Fig. 6). After 24 h,
cell shape and size was altered upon treatment with vari-
ous WIN concentrations (1 μM – 10 μM) and 2 % FCS
(data not shown). These alterations were pronounced
after 48 h and WIN concentrations above 2 μM induced
changed cell shape from spread out with lots of filopodia
to sharp-edged with a condensed nucleus and extensive
vacuolation (Fig. 6). This effect was highly dependent on
the presence of WIN, since wash-off and replacement of
culture medium with fresh medium containing 10 %
FCS fully reversed the effect within 24 h (Fig. 6).
Discussion
In this study the anti-inflammatory effects of WIN in
physiological (<1 μM) and high μM concentrations in
RASFs and OASFs were investigated. It was demonstrated
that WIN in concentrations below 1 μM decreases cyto-
kine and MMP-3 production via a TRPV1 and TRPA1
dependent pathway independent of cannabinoid receptors
type I and II (CB1 and CB2). This inhibitory effect of WIN
was much enhanced at concentrations above 4 μM and
was modulated only weakly by TRPV1/TRPA1 antagon-
ism suggesting additional WIN targets activated at high
concentrations. In OASFs but not RASFs, the effects of
micromolar WIN concentrations were partially inhibited
Fig. 4 Impact of fetal calf serum (FCS) content on the effects of
high concentrations of WIN55212-2 mesylate (WIN, 10−6M to 10−5M))
on TNF-induced IL-6 (a), IL-8 (b) and MMP-3 (c) production in RA and
OA synovial fibroblasts. Cytokine/MMP-3 production was determined
under hypoxic (1 % O2) conditions. ***p < 0.001, **p < 0.01, *p < 0.05
for comparisons vs WIN/TNF with 0 % FCS. The general linear model
with Bonferroni correction was used for all comparisons. All data are
given as mean ± sem
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by CB2 antagonism. High WIN concentrations also dem-
onstrated to impair SF adhesion and proliferation. The ob-
served effects of high WIN concentrations were reduced
by increasing FCS content in culture medium and cell
morphologic changes induced by WIN were reversed by
wash-off and replacement of culture medium without
WIN.
Studies regarding the effects of synthetic cannabinoids
on SFs were conducted by Selvi and colleagues who
showed a cannabinoid receptor independent reduction
of IL-6 and IL-8 production by high concentrations of
synthetic cannabinoids CP55,940 and WIN but this
study did not employ physiological concentrations of
both compounds [12]. Two more recent studies by Gui
and Fukuda employing different synthetic CB2 agonists
claimed that CB2 activation is responsible for the reduc-
tion of IL-6 and IL-8 production in SFs, but both studies
did not include antagonists [5, 8]. Furthermore the com-
pounds used in these studies were effective only in very
high concentrations (comparable to the high concentra-
tions of WIN used in this study), suggesting off-target
effects since their Ki values are in the low nanomolar
range. Here we provide evidence that the effects of low
WIN concentrations on TNF-induced IL-6, IL-8 and
MMP-3 production were dependent on activation/
desensitization of TRPV1 and TRPA1. The ability of
WIN to modulate TRPA1 channel activity has been de-
scribed in trigeminal neurons where WIN activates
TRPA1 which in turn modulates TRPV1 channel activity
via intracellular crosstalk [13, 14]. We found WIN to be
effective at concentrations as low as 10nM, somewhat
contradicting the Ki values reported for TRPA1 activa-
tion [15]. Since the binding site for WIN at TRPA1 is
intracellular it might be possible that WIN is accumu-
lated in the cytoplasm by binding to fatty acid binding
proteins. This phenomenon has already been described
for the endocannabinoid anandamide and plant cannabi-
noids delta9-tetrahydrocannabinol and cannabidiol [16].
In concentrations above 4 μM, we found WIN to com-
pletely block cytokine production. This is line with obser-
vations from other groups who showed similar effects in
SFs but also in monocytes/macrophages [12, 17]. The lat-
ter study demonstrated a site specific effect of WIN since
the enantiomer WIN55,212-3 mesylate was ineffective.
Our study suggests an influence of WIN on intracellular
calcium levels in SFs since BAPTA-Am, a calcium chelat-
ing agent, and TRPA1 antagonism (both treatments lower
calcium) attenuated the inhibitory effect on TNF-induced
cytokine production. Interestingly, CB2 antagonism par-
tially reversed the inhibitory effects of micromolar WIN
concentrations on IL-6 production in OASFs but not
RASFs and although IL-8 production was attenuated by
COR in OASFs and RASFs, the magnitude of inhibition
was greater in OASFs. This might be due to altered
Fig. 5 Influence of WIN55212-2 mesylate (WIN, 10−12M to 10−5M) on
adhesion under normoxia and proliferation under hypoxia of OA and
RA synovial fibroblasts. a Impact of WIN on OASF and RASF adhesion
to fibronectin. b Impact of WIN on OASF and RASF proliferation. The
general linear model with Bonferroni correction was used for all
comparisons. The dotted line represents the control level without
(tissue culture medium only) which was set to 100 %. Fig. 4a, b:
Data are given as mean ± sem. The boundary of the box closest
to zero indicates the 25th percentile, the line within each box
indicates the median and the upper boundary of the box the
75th percentile; WIN data are given as median. Error bars below and
above the boxes indicate the 10th and 90th percentiles. Fig. 4a:
***p < 0.001 for comparisons vs control. Fig. 4b: ***p < 0.001 for
comparisons vs control, (WIN 2 μM to 10 μM only)
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intracellular signaling or desensitization of CB2 in RASFs.
Previous studies already found specific hypomethylation
patterns in RASFs supporting their characteristic “trans-
formed” phenotype [18]. One of these changes might dir-
ectly or indirectly impact CB2 signaling pathways.
In concentrations above 8 μM, the effects of WIN were
no longer inhibited by CB2 antagonism, suggesting a dif-
ferent cellular target. Data from Bloom et. al demonstrate
that WIN and other cannabinoids alter membrane
polarization and many off-target effects of cannabinoids
are only evident at concentrations that cause membrane
perturbations [19]. This suggests that WIN and other can-
nabinoids alter the lipid environment of other receptors
and thereby influence their accessibility to respective li-
gands [20]. Furthermore, the activity of adenylyl cyclase is
enhanced by changes in membrane ordering counteract-
ing the inhibitory effect of classical cannabinoid recep-
tors on cAMP. [21]. In this study, we showed that
the induction of autophagy by the AMPK activator
metformin attenuated the effects of WIN on TNF-
induced IL-6 production in RASFs, suggesting cellular
energy perturbations. The observed increase in TNF-
induced MMP-3 after treatment with high WIN concentra-
tions is in contrast to observations in U937 macrophages,
where WIN decreases extracellular MMP-9 [17].
We found fetal calf serum (FCS) content in culture
medium to modulate the efficacy of WIN up to concentra-
tions of 6 μM, with high FCS being protective. This effect
was also evident in breast cancer cells where serum free
conditions enhanced the potency of WIN threefold [22].
The protective effect of serum might derive from en-
hanced WIN binding to serum proteins thereby slowing
exposure to the compound.
In previous studies we found CB1 and CB2 agonism to
support SF adhesion to fibronectin [11]. In concentrations
up to 100nM, WIN also increased adhesion of RASFs and
OASFs, likely via activation of classical cannabinoid recep-
tors. In concentrations above 1 μM however, adhesion
was decreased reflecting studies by Zhao that showed de-
creased adhesion of macrophages after WIN treatment
[23]. Furthermore the beneficial effects of WIN in a
chronic model of multiple sclerosis were partially medi-
ated by down-regulating adhesion molecules VCAM-1
and ICAM-1 [24]. Interestingly, adhesion was maximally
stimulated at WIN concentrations that were most effective
in reducing IL-6 and IL-8 production (10−9M/10−8M). Con-
flicting results have been published as to whether CB2 acti-
vation enhances or decreases adhesion. While 2-AG and
WIN increased adhesion of HL-60 macrophage-like cells to
fibronectin, monocyte-endothelial cell adhesion was de-
creased by CB2 activation [25, 26]. This might depend on
different adhesion molecules involved in these studies. Our
results obtained with adhesion of SFs to fibronectin con-
firmed results of Gokoh et. al. Data from the literature
suggest that integrin-driven adhesion is enhanced, but ad-
hesion via VCAM1 and ICAMs is reduced by CB2 agonism
[11, 26, 27]. Furthermore, adhesion might be influenced by
the ligand used and biased agonism has been reported for
CB1 and other GPCRs [28, 29]. Proliferation was modulated
in a similar fashion with μM concentrations of WIN being
inhibitory. This effect has been described in breast cancer
cells and hepatocarcinoma cells albeit the latter study at-
tributed the effect to PPAR-γ activation [22, 30]. Interest-
ingly, other cannabinoids also provided non-cannabinoid
receptor mediated anti-proliferative effects similar to those
of WIN [31].
Changes in adhesion and proliferation with high dose
WIN treatment was accompanied by changes in cell
morphology leading to sharp edged cell bodies, con-
densed nuclei and extensive vaculolation. This is in line
Fig. 6 Cell morphologic changes of RA synovial fibroblasts after 48 h incubation with WIN (0 μM, 1 μM, 10 μM). Arrows indicate vacuolization; the
black rimmed cell is an example of sharp edged cell bodies in contrast to unstimulated control fibroblasts. Regenerated =WIN wash-off after 48 h
and supplementation with fresh medium containing 10 % FCS without WIN
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with observations in mantle cell lymphoma cells which
responded similar to WIN [32]. In this study, the au-
thors did not find any apoptotic markers but attributed
cell death to paraptosis. This confirms our results since
we did not detect any increases in lactate dehydrogenase
(marker for general cell death) or caspase-3/7 (marker
for apoptosis) but an increase in propidium iodide bind-
ing (marker for general cell death). High concentrations
of WIN might mediate paraptosis by changes in mem-
brane fluidity, since this might disrupt cellular processes
required for cell survival [19–21].
Conclusion
In this report we demonstrated anti-inflammatory effects
of the synthetic cannabinoid WIN in low and high con-
centrations. While low WIN concentrations mediated ef-
fects via TRP channels, high concentrations were fully
inhibitory on cell function and this was mediated via a
site specific but yet unidentified receptor target. For
therapeutic use, identification of this low-affinity WIN
site of action might pose an attractive target especially
when WIN is administered directly in the joint to
achieve high local concentrations. Besides inhibiting cell
function via its low affinity binding site, WIN also acti-
vates cannabinoid receptors 1 and 2 which have been
shown to reduce (arthritic) inflammation [5, 33]. Fur-
thermore, this study demonstrated anti-inflammatory ef-
fects via modulation of TRP channels by WIN. Together,
inactivation of TRPs and activation of cannabinoid re-
ceptors might also reduce the sensation of pain, which
further underlines the potential of WIN in the treatment
of chronic inflammation.
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